Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma

van Doesum JA, Niezink AGH, Huls GA, Beijert M, Diepstra A, van Meerten T. Extranodal Natural Killer/T-cell Lymphoma. Nasal Type: Diagnosis and Treatment Hemasphere. 2021;5:e523.

PubMed  Google Scholar 

Wang H, Fu BB, Gale RP, Liang Y. NK-/T-cell lymphomas. Leukemia. 2021;35:2460–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tse E, Kwong YL. How I treat NK/T-cell lymphomas Blood. Blood. 2013;121:4997–5005.

Article  CAS  PubMed  Google Scholar 

Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng RJ, Wong EKY, Cheah DMZ, Chia BKH, Iqbal J, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia. 2020;34:3413–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131:2528–40.

Article  CAS  PubMed  Google Scholar 

Tse E, Au-Yeung R, Kwong YL. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. Expert Rev Hematol. 2019;12:927–35.

Article  CAS  PubMed  Google Scholar 

Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19:79.

Article  PubMed  PubMed Central  Google Scholar 

Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC, Kucuk C, Deffenbacher K, Vose J, Smith L, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 2011;25:348–58.

Article  CAS  PubMed  Google Scholar 

Huang Y, de Reynies A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, Bosq J, Briere J, Petit B, Thomas E, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115:1226–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011;223:496–510.

Article  CAS  PubMed  Google Scholar 

Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, Zhong HJ, Cheng S, Ou-Yang BS, Hu Y, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell. 2020;37(403–419):e406.

Google Scholar 

Somasundaram N, Lim JQ, Ong CK, Lim ST. Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL). J Hematol Oncol. 2019;12:28.

Article  PubMed  PubMed Central  Google Scholar 

Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood. 2018;131:2320–30.

Article  PubMed  Google Scholar 

Li B, Yan J, Phyu T, Fan S, Chung TH, Mustafa N, Lin B, Wang L, Eichhorn PJA, Goh BC, et al. MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. Blood. 2019;134:2046–58.

Article  PubMed  Google Scholar 

Yan J, Li B, Lin B, Lee PT, Chung TH, Tan J, Bi C, Lee XT, Selvarajan V, Ng SB, et al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood. 2016;128:948–58.

Article  CAS  PubMed  Google Scholar 

Yan J, Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood. 2013;121:4512–20.

Article  CAS  PubMed  Google Scholar 

Selvarajan V, Osato M, Nah GSS, Yan J, Chung TH, Voon DC, Ito Y, Ham MF, Salto-Tellez M, Shimizu N, et al. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. Leukemia. 2017;31:2219–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, Perrot C, Vieillard V, Dartigues P, Gaulard P, et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia. 2009;23:1667–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kucuk C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W, Lack N, Alkan C, Williams JC, Avery KN, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015;6:6025.

Article  CAS  PubMed  Google Scholar 

de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB. Molecular pathogenic pathways in extranodal NK/T cell lymphoma. J Hematol Oncol. 2019;12:33.

Article  PubMed  PubMed Central  Google Scholar 

Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, Bi C, Tan J, Kwong YL, Shimizu N, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 2011;118:4919–29.

Article  CAS  PubMed  Google Scholar 

Kucuk C, Hu X, Jiang B, Klinkebiel D, Geng H, Gong Q, Bouska A, Iqbal J, Gaulard P, McKeithan TW, Chan WC. Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin Cancer Res. 2015;21:1699–711.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Liang L, Li D, Nong L, Liu J, Qu L, Zheng Y, Zhang B, Li T. Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation. Hematol Oncol. 2017;35:645–54.

Article  CAS  PubMed  Google Scholar 

Lim JQ, Huang D, Chan JY, Laurensia Y, Wong EKY, Cheah DMZ, Chia BKH, Chuang WY, Kuo MC, Su YJ, et al. A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort. Am J Hematol. 2022;97:1159–69.

Article  CAS  PubMed  Google Scholar 

Bhagwat AS, Lu B, Vakoc CR. Enhancer dysfunction in leukemia. Blood. 2018;131:1795–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andre KM, Sipos EH, Soutourina J. Mediator Roles Going Beyond Transcription. Trends Genet. 2021;37:224–34.

Article  CAS  PubMed  Google Scholar 

Donati B, Lorenzini E, Ciarrocchi A. BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17:164.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeh CH, Bellon M, Wang F, Zhang H, Fu L, Nicot C. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Mol Cancer. 2020;19:139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia Y, Chng WJ, Zhou J. Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. J Hematol Oncol. 2019;12:77.

Article  PubMed  PubMed Central  Google Scholar 

Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, et al. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Blood. 2017;130:2326–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong RWJ, Tan TK, Amanda S, Ngoc PCT, Leong WZ, Tan SH, Asamitsu K, Hibi Y, Ueda R, Okamoto T, et al. Feed-forward regulatory loop driven by IRF4 and NF-kappaB in adult T-cell leukemia/lymphoma. Blood. 2020;135:934–47.

Article  PubMed  Google Scholar 

Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011;118:2830–9.

Article  PubMed  Google Scholar 

Zhou J, Toh SH, Chan ZL, Quah JY, Chooi JY, Tan TZ, Chong PSY, Zeng Q, Chng WJ. A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/beta-catenin pathways for treatment of AML with high PRL-3 phosphatase. J Hematol Oncol. 2018;11:36.

Article  PubMed  PubMed Central  Google Scholar 

Wai CMM, Chen S, Phyu T, Fan S, Leong SM, Zheng W, Low LCY, Choo SN, Lee CK, Chung TH, et al. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica. 2022;107:1864–79.

Article 

留言 (0)

沒有登入
gif